Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Lead

Hillhurst Biopharmaceuticals, Inc.

With

• The Parkinson Study Group
• Massachusetts General Hospital (PI: Michael Schwarzschild MD,PhD, Co-PI: Stephen Gomperts MD,PhD)
• Michael J. Fox Foundation for Parkinson's Research